FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379284490> ?p ?o ?g. }

• W4379284490 endingPage "e12532" @default.
• W4379284490 startingPage "e12532" @default.
• W4379284490 abstract "e12532 Background: The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) define a biosimilar as a biological molecule product that is highly similar to and has no clinically meaningful differences from an existing approved reference product. The trastuzumab biosimilar was the first oncology biosimilar approved in Brazil for HER2-positive breast cancer (BC) and advanced gastric cancer treatment. This study aimed to assess the effectiveness and safety of trastuzumab biosimilar (named as Zedora in Brazil) in the adjuvant setting among HER2-positive BC patients. Methods: This is a national, multicentric, observational, and prospective real-world study. Patients with early-stage HER2-positive BC who received at least one dose of trastuzumab biosimilar as adjuvant therapy were eligible. At the present date, 162 of 170 planned patients were recruited. Here, we present the preliminary safety data of the first 59 patients recruited in the study. The safety endpoint is the occurrence of adverse events (AEs), and the safety population included all patients who received at least one dose of trastuzumab biosimilar. We analyzed the AEs collected from the signature of the consent form until the end of adjuvant treatment. Results: Baseline patient characteristics among the 59 evaluated patients included a mean age of 51.7 ± 12.9 years, with 79.7% of them having a node-negative disease. Most patients had hormone-receptor-positive tumors (67.8% estrogen-receptor-positive and 55.9% progesterone-receptor-positive). The number of patients undergoing conservative surgery (67.8%) was higher than mastectomy (32.2%). The most frequent histological BC subtype was invasive ductal carcinoma (98.3%). All 59 participants received adjuvant anti-HER2 therapy, that included trastuzumab biosimilar administration trastuzumab biosimilar + pertuzumab (22.0%), and only two patients were receiving reference trastuzumab, which was switched to trastuzumab biosimilar upon entry into the study. The duration of adjuvant anti-HER2 therapy was 10.2 ± 2.2 months, ranging from 5.8 to 13.9 months. This time corresponds to, on average, 14 ± 3.2 cycles of 21 days. In total, 78.0% of the patients had at least one AE, four of them were serious AEs (6.8%), including three of severe intensity and one life-threatening. Table 1 lists the most reported AEs according to SOC (System Organ Class). Conclusions: The nature and severity of AEs observed to trastuzumab biosimilar were consistent with the known safety profile of trastuzumab. Clinical trial information: NCT03892655 . [Table: see text]" @default.
• W4379284490 created "2023-06-05" @default.
• W4379284490 creator A5005326550 @default.
• W4379284490 creator A5022938970 @default.
• W4379284490 creator A5037550979 @default.
• W4379284490 creator A5042797902 @default.
• W4379284490 creator A5053129190 @default.
• W4379284490 creator A5053195291 @default.
• W4379284490 creator A5064252296 @default.
• W4379284490 date "2023-06-01" @default.
• W4379284490 modified "2023-09-25" @default.
• W4379284490 title "A prospective real-world study to assess the effectiveness and safety of trastuzumab biosimilar in the adjuvant treatment of HER2-positive breast cancer: Preliminary safety results." @default.
• W4379284490 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.e12532" @default.
• W4379284490 hasPublicationYear "2023" @default.
• W4379284490 type Work @default.
• W4379284490 citedByCount "0" @default.
• W4379284490 crossrefType "journal-article" @default.
• W4379284490 hasAuthorship W4379284490A5005326550 @default.
• W4379284490 hasAuthorship W4379284490A5022938970 @default.
• W4379284490 hasAuthorship W4379284490A5037550979 @default.
• W4379284490 hasAuthorship W4379284490A5042797902 @default.
• W4379284490 hasAuthorship W4379284490A5053129190 @default.
• W4379284490 hasAuthorship W4379284490A5053195291 @default.
• W4379284490 hasAuthorship W4379284490A5064252296 @default.
• W4379284490 hasConcept C121608353 @default.
• W4379284490 hasConcept C126322002 @default.
• W4379284490 hasConcept C143998085 @default.
• W4379284490 hasConcept C197934379 @default.
• W4379284490 hasConcept C2777863537 @default.
• W4379284490 hasConcept C2779786085 @default.
• W4379284490 hasConcept C2908647359 @default.
• W4379284490 hasConcept C530470458 @default.
• W4379284490 hasConcept C59491497 @default.
• W4379284490 hasConcept C71924100 @default.
• W4379284490 hasConcept C99454951 @default.
• W4379284490 hasConceptScore W4379284490C121608353 @default.
• W4379284490 hasConceptScore W4379284490C126322002 @default.
• W4379284490 hasConceptScore W4379284490C143998085 @default.
• W4379284490 hasConceptScore W4379284490C197934379 @default.
• W4379284490 hasConceptScore W4379284490C2777863537 @default.
• W4379284490 hasConceptScore W4379284490C2779786085 @default.
• W4379284490 hasConceptScore W4379284490C2908647359 @default.
• W4379284490 hasConceptScore W4379284490C530470458 @default.
• W4379284490 hasConceptScore W4379284490C59491497 @default.
• W4379284490 hasConceptScore W4379284490C71924100 @default.
• W4379284490 hasConceptScore W4379284490C99454951 @default.
• W4379284490 hasIssue "16_suppl" @default.
• W4379284490 hasLocation W43792844901 @default.
• W4379284490 hasOpenAccess W4379284490 @default.
• W4379284490 hasPrimaryLocation W43792844901 @default.
• W4379284490 hasRelatedWork W2761356983 @default.
• W4379284490 hasRelatedWork W2794649617 @default.
• W4379284490 hasRelatedWork W2794755138 @default.
• W4379284490 hasRelatedWork W2934222321 @default.
• W4379284490 hasRelatedWork W2947599283 @default.
• W4379284490 hasRelatedWork W3095802045 @default.
• W4379284490 hasRelatedWork W3137327078 @default.
• W4379284490 hasRelatedWork W3202363710 @default.
• W4379284490 hasRelatedWork W4292478226 @default.
• W4379284490 hasRelatedWork W2342209702 @default.
• W4379284490 hasVolume "41" @default.
• W4379284490 isParatext "false" @default.
• W4379284490 isRetracted "false" @default.
• W4379284490 workType "article" @default.